Loading
Life sciences · Journal article
Consilium Medicum · September 8, 2026
A consensus or society position rather than new primary data.
This is a summary of an expert council meeting held in Moscow to review clinical and preclinical data on tedixaban, a Russian-developed factor Xa inhibitor. The meeting presented findings from Phase II and III trials in post-major joint replacement patients, a randomized controlled trial in hospitalized COVID-19 patients, and pharmacogenetic data, and endorsed its incorporation into Russian clinical guidelines for VTE prevention. The source does not itself present primary trial data, effect sizes, or comparative efficacy results; it describes what was presented and reviewed.
Journal article. Patients undergoing major joint replacement; hospitalized COVID-19 patients; potential expansion to atrial fibrillation patients and those with established VTE.. Intervention: Tedixaban (Russian-made selective factor Xa inhibitor).. Moscow, Russia (meeting location); Russian clinical context..
Phase II and III trial outcomes in patients after major joint replacement supported efficacy and favorable safety profile of tedixaban in VTE prevention. Multicenter, prospective, randomized controlled trial data in hospitalized COVID-19 patients were presented as foundation for incorporation into Russian Ministry of Health clinical guidelines. Experts identified expansion of indications to atrial fibrillation patients and investigation of established VTE treatment as priority research areas.
No efficacy or safety point estimates, confidence intervals, or p-values reported for any trial mentioned. Phase II and III trial outcomes in patients after major joint replacement supported efficacy and favorable safety profile of tedixaban in VTE prevention.
This meeting summary reflects Russian expert consensus on tedixaban's role in VTE prevention and its recent incorporation into national clinical guidelines. However, the source does not provide specific efficacy data, effect sizes, or comparative outcomes needed for clinicians outside the Russian context to evaluate its clinical utility relative to established factor Xa inhibitors.
This is a summary of an expert council meeting reviewing clinical data on tedixaban; it presents existing trial results and clinical guidance rather than new primary research evidence.
As stated by the source record.
This meeting summary reflects Russian expert consensus on tedixaban's role in VTE prevention and its recent incorporation into national clinical guidelines. However, the source does not provide specific efficacy data, effect sizes, or comparative outcomes needed for clinicians outside the Russian context to evaluate its clinical utility relative to established factor Xa inhibitors.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Venous thromboembolic complications (VTE) constitute a significant cause of morbidity and mortality globally. In light of the widespread use of direct oral anticoagulants, the ongoing development of novel factor Xa inhibitors remains pertinent for enhancing the pharmacological properties of these agents, broadening options for preventing and treating thrombotic complications, and advancing Russian-based pharmaceutical technologies. On May 18, 2026, an Expert Council meeting titled "Russian-made Coagulation Factor Xa Inhibitor Tedixaban: Clinical Data and Prospects" convened in Moscow, gathering specialists in clinical pharmacology, cardiology, vascular surgery, and infectious diseases. The primary objective of the meeting was to examine current data regarding tedixaban, analyze the findings of completed clinical trials, and delineate priority areas for its future clinical research. Presentations at the meeting included information on the development of the first original Russian selective factor Xa inhibitor, along with insights into the drug's pharmacological attributes and safety profile as determined from preclinical studies. Additionally, the outcomes of phase II and III clinical trials involving patients after major joint replacement were discussed, supporting the efficacy and favorable safety profile of tedixaban in VTE prevention. The findings of a multicenter, prospective, randomized controlled trial assessing the drug in hospitalized COVID-19 patients were presented, providing a foundation for its incorporation into the current clinical guidelines issued by the Ministry of Health of Russia. The meeting also underscored the potential to expand approved indications for tedixaban, including its use in patients with atrial fibrillation, and investigations into its effectiveness in treating established VTE. Pharmacogenetic study outcomes that might inform the personalized selection of direct oral anticoagulants, including tedixaban, were also discussed. In conclusion, the experts summarized recent data on the clinical application of tedixaban, identified key avenues for continued development of its clinical program, and articulated an executive summary reflecting the current understanding of the drug's role in the prevention of thrombotic complications.